Article Text

other Versions

Economic evaluation alongside the Premature Infants in Need of Transfusion randomised controlled trial
  1. Karen L Kamholz1,2,
  2. Dmitry Dukhovny3,4,
  3. Haresh Kirpalani5,6,
  4. Robin K Whyte7,
  5. Robin S Roberts6,
  6. Na Wang4,
  7. WenYang Mao4,
  8. John A F Zupancic3,4,
  9. the Premature Infants in Need of Transfusion Study Group
  1. 1Department of Pediatrics, Boston Medical Center, Boston, Massachusetts, USA
  2. 2Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts, USA
  3. 3Division of Newborn Medicine, Harvard Medical School, Boston, Massachusetts, USA
  4. 4Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
  5. 5Division of Neonatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
  6. 6Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
  7. 7Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
  1. Correspondence to Karen L Kamholz, Assistant Professor of Pediatrics, Division of Neonatology, Boston Medical Center, 771 Albany Street, Dowling 4N, Room 4113, Boston, MA 02118, USA; karen.kamholz{at}


Background The Premature Infants in Need of Transfusion (PINT) Outcome Study showed no significant difference in the primary outcome of death or neurodevelopmental impairment (NDI) in extremely low birthweight (ELBW) infants. However, a post-hoc analysis expanding the definition of NDI to include borderline intellectual functioning (Mental Development Index (MDI) <85) found an improvement in outcomes in the group maintained at higher haemoglobin levels.

Objective To determine the cost effectiveness of more frequent red blood cell transfusions (high-Hb threshold) compared with less frequent transfusions (low-Hb threshold) in ELBW infants.

Design/methods The authors performed an economic evaluation using patient-level data collected during the PINT randomised trial. The authors measured comprehensive costs from a third-party payer's perspective over a time horizon from birth through 18–21 months corrected age.

Results The average total cost in the high-Hb threshold group was CAN$149 767 compared with CAN$150 227 in the low-Hb threshold group (difference of CAN$460, p=0.96). Cost-effectiveness analysis estimated savings of CAN$6879 for every additional infant surviving without severe NDI. There was a 48% chance that the high-Hb threshold reduced costs while improving outcome and a 90% chance that it would be cost effective at a willingness-to-pay threshold of CAN$250 000 per additional survivor without severe NDI. Post-hoc analysis defining cognitive delay as MDI score <85, instead of <70, revealed savings in the high-Hb threshold group of CAN$4457 per additional survivor without NDI. Results were robust to deterministic sensitivity analyses.

Conclusion A high-Hb threshold for transfusion, as measured in ELBW PINT study infants through 18 months corrected gestational age, may be an economically appealing intervention. The estimates were associated with moderate statistical uncertainty that should be targeted in larger, future studies.

Statistics from


  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.